Omnicare appointed James Pusey as president and CEO of Omnicare Clinical Research. In his new position, Pusey will be responsible for Omnicare’s contract research organization (CRO) operations worldwide.

Pusey succeeds Dr. Dale B. Evans, who has resigned to pursue other opportunities. 

“Dr. Pusey has a wealth of experience in all aspects of the CRO business—from research and drug development to operations, sales and customer relationships—and we believe he will add significant value to our organization,” said Joel Gemunder, Omnicare’s president and CEO.

“Under Dr. Pusey’s leadership, we look forward to leveraging the organization’s assets to further strengthen Omnicare’s presence in the clinical research business, and to develop new growth opportunities. “Omnicare’s CRO operations, including Omnicare Clinical Research, headquartered in King of Prussia, Penn., and Clinimetrics Research Associates, based in San Jose, Calif., provide comprehensive product development and research services.

Pusey added, “Omnicare has a CRO platform that not only has a full complement of drug development and commercialization services across a broad global footprint but also has unique opportunities in the biotech arena and in geriatric research. I am encouraged by the long-term outlook for the CRO industry and by the prospects inherent in Omnicare’s CRO business.”